Endocyte Inc., 3000 Kent Ave., Suite A1-100, West Lafayette 47906, is a biopharmaceutical company developing therapies for the treatment of cancer and inflammatory diseases. The company reported a net loss of $20.1 million, or $21.77 per share, on no revenue in the year ended Dec. 31, 2010. That compares with a net loss of $17.0 million, or $18.67 a share, on revenue of $3.0 million in the same period a year earlier. The company’s website is www.endocyte.com. Endocyte launched its initial public offering at $6 a share on Feb. 4. The stock trades on Nasdaq under the ticker EYCT. Information for Proxy Corner was taken from Yahoo!?Finance and from the company’s proxy statement dated April 15, 2011. View full Proxy Corner feature
Please enable JavaScript to view this content.